从事代谢性骨病研究10年。迄今发表SCI论文60篇，其中第一作者或通讯作者SCI论著15篇，包括《Nat Med》（最新IF值=28.054）1篇、《J Clin Invest》（最新IF值=13.765）1篇、《J Bone Miner Res》（最新IF值=6.589）1篇等。2015年入选国家“青年千人计划”。获Webster Jee奖、国际骨矿盐疾病学术会议最佳论文奖、湖南省优博等。现任中南大学湘雅医院“青年千人计划”特聘教授，担任“运动系统损伤修复研究中心”主任。我们最近发表于《Nat Med》的研究成果揭示了骨代谢“三元调控”新理论：基于破骨前体细胞的骨血管生成-骨形成-骨吸收偶联调控。基于此理论突破，本项目拟从分子、细胞和整体层面进一步研究破骨前体细胞促进剂哈尔明碱调控骨代谢的作用效果与机制，将为基于我们原创性“三元调控”理论的新型骨质疏松防治药物的筛选和开发奠定理论基础。

I have been engaged in bone metabolism research for ten years. So far, I have published 60 SCI papers. I have published 16 first/corresponding SCI papers including one Nat Med, one J Clin Invest, one J Bone Miner Res, et al. I was recruited as an expert of the “Thousand Youth Talent Program” in 2015. I got the International Chinese Musculoskeletal Research Society Webster Jee Young Investigator Award, the Best Paper Award of the 7th International Conference on Osteoporosis and Bone Research, the Hunan Province Excellent Doctoral Dissertation Award. Currently, I am the distinguished professor of the “Thousand Youth Talent Program” in Second Xiangya Hospital, Central South University, as the director of the “Movement System Repair Research Center”. Our recent Nat Med publication revealed a novel bone metabolism regulation mode: preosteoclast-initiated regulation of coupling of bone angiogenesis-bone formation-bone resorption. Base on this theoretical breakthrough, the current proposal aims to further investigate the efficacy and mechanism of the action of harmine, a preosteoclast agonist, on bone metabolism at the molecular, cellular, and whole-body levels, then in favour of establishing theoretical foundation for the discovery and development of our original novel theory-based new anti-osteoporosis drugs.